Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Drug Royalty Corporation (DRI-TSE) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Neidhardt who wrote (80)	3/25/1999 7:39:00 AM
From: BioInv	Read Replies (1) \| Respond to of 96

A couple of possible reasons. A] Their three year corporate plan requires a large level of investment [$175 M]in royalty deals. That implies finding at least $100 M extra capital from debt , equity or retained earnings. B]The stock price has risen 30% to 50% in the last few months. They may feel that $2.25 is the best price they can get in the short run for an equity financing.. and future equity placements might have to be made at a lower price if the general market corrects.